Patents Examined by Aaron Priest
  • Patent number: 11440012
    Abstract: A system (1) for infectious disease screening. The system is for use with an assay device (2) which incorporates an ultrasonic transducer for generating ultrasonic waves to lyse cells in a biological sample. The system (1) comprises a frequency control module which is configured to control the ultrasonic transducer (49) to oscillate at an optimum frequency for cell lysis, a PCR arrangement (16) which is configured to receive and amplify the DNA from the sample; and a detection arrangement (70) which is configured to detect the presence of an infectious disease in the amplified DNA and to provide an output which is indicative of whether or not the detection arrangement (70) detects the presence of an infectious disease in the amplified DNA.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: September 13, 2022
    Assignee: Shaheen Innovations Holding Limited
    Inventors: Mohammed Alshaiba Saleh Ghannam Almazrouei, Imad Lahoud, Sajid Bhatti, Jeff Machovec, Dinil Divakaran
  • Patent number: 11434539
    Abstract: A method of diagnosing bacterial vaginosis in a woman, which involves determining an amount of each of more than one BV-associated bacterium in a vaginal sample obtained from the female and assessing a BV status of the female based on the amount of each of the more than one BV-associated bacterium in the sample
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: September 6, 2022
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Charles Paul Cartwright, Bryndon Denae Lembke, Kalpana Ramachandran
  • Patent number: 11434527
    Abstract: The present invention provides a method for detecting mycoplasma, which can directly confirm whether a cell is infected with mycoplasma, by simultaneously amplifying DNA extracted from lysing a host cell infected with mycoplasma, and mitochondrial DNA in the cytoplasm of the host cell. According to the method of the present invention, by directly using the DNA inside the host cell, the DNA of mycoplasma bound around the nucleus of the host cell can be used as an amplification target, thereby increasing detection sensitivity. In addition, since the mitochondrial DNA inside the host cell is used as an amplification target of an internal control sample, whether the sample has been sampled in an appropriate amount can be confirmed in a convenient manner, and furthermore, by comparing the band size between the internal control sample and the mycoplasma DNA, the degree of mycoplasma infection can be quantitatively confirmed.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: September 6, 2022
    Assignees: The Asan Foundation, University of Ulsan Foundation for Industry Cooperation
    Inventors: Eun Ju Kang, Yeon Mi Lee
  • Patent number: 11427862
    Abstract: Oligonucleotides may be universal primers and probes. Method may use these oligonucleotides for detecting or detecting and quantifying a nucleic acid acting as a universal internal control. A primer pair includes a first primer having SEQ ID NO: 1 or a complement thereof and a second primer having SEQ ID NO: 2 or a complement thereof. A probe includes SEQ ID NO: 3 or a complement thereof, preferably wherein each of the nucleotides in position 4, 5, 6, 8, 9, 10, 11 and 12 of SEQ ID NO: 3 is replaced with a corresponding locked nucleic acid (LNA) unit (SEQ ID NO: 4).
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: August 30, 2022
    Assignee: CENTRO DI SPERIMENTAZIONE LAIMBURG
    Inventors: Vicky Oberkofler, Katrin Janik
  • Patent number: 11427865
    Abstract: Provided herein are methods and systems for absolute quantification of a target 16S rRNA and/or of a target prokaryotic taxon, based on amplifying and sequencing a same 16S rRNA recognition segment in which target 16S rRNA conserved regions flank 16S rRNA variable regions, conserved and variable among a plurality of sample 16S rRNAs and/or of a sample prokaryotic taxon of higher taxonomic rank with respect to the target taxon. In the methods and systems, absolute abundance of the a plurality of sample 16S rRNAs and/or of the sample prokaryotic taxon detected by the amplifying, is multiplied by the relative abundance of the target 16S rRNA and/or of a target prokaryotic taxon detected by the sequencing to provide the absolute quantification in accordance with method and systems of the disclosure.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: August 30, 2022
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Rustem F Ismagilov, Jacob T Barlow, Said R. Bogatyrev
  • Patent number: 11421238
    Abstract: The present invention relates to a method for introducing mutations into at least one target nucleic acid molecule comprising (a) providing at least one sample comprising at least one target nucleic acid molecule; and (b) amplifying the at least one target nucleic acid molecule using a low bias DNA polymerase. The present further relates to a use of a low bias DNA polymerase in a method for introducing mutations into one or more nucleic acid molecule(s), a group of sample tags, a method for designing the group of sample tags, a computer readable medium, and a method for preferentially amplifying target nucleic acid molecules.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 23, 2022
    Assignee: LONGAS TECHNOLOGIES PTY LTD
    Inventors: Leigh G. Monahan, Joyce To, Catherine M. Burke, Michael Imelfort, Aaron E. Darling
  • Patent number: 11421284
    Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: August 23, 2022
    Assignee: Allarity Therapeutics Europe ApS
    Inventor: Steen Knudsen
  • Patent number: 11421216
    Abstract: The present disclosure is related to methods and materials for depleting unwanted RNA species from a nucleic acid sample. In particular, the present disclosure describes how to remove unwanted rRNA, tRNA, mRNA or other RNA species that could interfere with the analysis, manipulation and study of target RNA molecules in a sample.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 23, 2022
    Assignee: ILLUMINA, INC.
    Inventors: Scott Kuersten, Frederick W. Hyde, Asako Tetsubayashi
  • Patent number: 11414658
    Abstract: A tracer particle is provided. The tracer particle includes: a core structure; a nucleic acid molecule immobilized on the core structure; and a shell layer covering the core structure and the nucleic acid molecule; wherein the core structure has a first porosity, the shell layer has a second porosity, and the first porosity is greater than the second porosity.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 16, 2022
    Assignee: Industrial Technology Research Institute
    Inventors: Kai-Chun Fan, Yin-Lung Han, Pei-Jyuan Gao, Yong-Yang Lin, Chieh-Lun Cheng, Chien-Chang Huang, Yung-Ho Chang, Chia-Long Lin, I-Son Ng, Bo-Han Chen
  • Patent number: 11414687
    Abstract: The present disclosure relates to methods, processes and systems for enzymatic synthesis of oligonucleotide from a single-stranded, immobilized primer in the presence of a polymerase. Using the disclosed methods single-stranded oligonucleotides can be synthesized enzymatically from a single-stranded, immobilized primer in the presence of deoxyribonucleotide triphosphates or ribonucleotide triphosphates. Dideoxyribonucleotide triphosphates, deoxyribonucleotide triphosphates with reversible terminators, or ribonucleotide triphosphates with reversible terminators can be added enzymatically to the end of the primer or its extension products. According to the disclosed method, a single-stranded primer can bind to a template such that the thus-formed double-stranded structure can allow the polymerase to extend the primer at 3? end.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 16, 2022
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Kendall Hoff, Michelle Halpain, Giancarlo Garbagnati, Wei Zhou
  • Patent number: 11414710
    Abstract: The present technology provides polynucleotide compositions and methods of using the same to detect circulating tumor DNA (ctDNA) in a patient. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: August 16, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Suzzette Arnal, Taraneh Angeloni
  • Patent number: 11414698
    Abstract: Disclosed herein is a method of quantifying a mutant allele burden of a target gene in a subject. The method includes providing a first plasmid that includes a mutant allele sequence and an internal control sequence, and a second plasmid that includes a wild-type allele sequence and the internal control sequence, and subjecting DNA of the subject to quantitative polymerase chain reaction to measure a mutant allele expression level of the target gene, so as to determine the mutant allele burden of the target gene in the subject based on a standard curve of the mutant allele burden of the target gene created by serial dilution of the first and second plasmids.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: August 16, 2022
    Assignee: CHANG GUNG MEDICAL FOUNDATION CHANG GUNG MEMORIAL HOSPITAL AT CHIAYI
    Inventors: Chih-Cheng Chen, Chia-Chen Hsu
  • Patent number: 11408020
    Abstract: The present invention relates to methods of joining two or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro, wherein the distal region of the first DNA molecule and the proximal region of the second DNA molecule of each pair share a region of sequence identity. The method allows the joining of a large number of DNA fragments, in a predetermined order and orientation, without the use of restriction enzymes. It can be used, e.g., to join synthetically produced sub-fragments of a gene or genome of interest. Kits for performing the method are also disclosed. The methods of joining DNA molecules may be used to generate combinatorial libraries useful to generate, for example, optimal protein expression through codon optimization, gene optimization, and pathway optimization.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 9, 2022
    Assignee: Codex DNA, Inc.
    Inventors: Daniel G. Gibson, Hamilton O. Smith, Clyde A. Hutchison, Lei Young, J. Craig Venter
  • Patent number: 11410747
    Abstract: The invention relates to a method of estimating a nucleic acid copy number after amplification comprising the steps of providing a sample comprising nucleic acids of a to be determined number of copies; attaching variable labels to said nucleic acids; amplifying said nucleic acids with the labels with a nucleic acid duplication procedure, preferably PCR; determining amounts of amplified nucleic acid copies with a label, each amount is determined for nucleic acid copies with a different label; and providing an estimation of the nucleic acid copy number in the sample based on the determined amounts of amplified nucleic acid copies; as well as computer program products adapted for performing such methods.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 9, 2022
    Assignee: LEXOGEN GMBH
    Inventors: Andreas Turk, Michael Moldaschl
  • Patent number: 11401546
    Abstract: The present invention relates to the detection of a target nucleic acid sequence by a PTOCE-E (PTO Cleavage and Extension-dependent Extension) assay. The PTOCE-E assay of the present invention can reduce the non-target signal and increase the target signal as compared with the conventional PTOCE and PCE-SH methods, thereby enabling more accurate detection of the target nucleic acid sequence.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 2, 2022
    Assignee: SEEGENE, INC.
    Inventors: Young Jo Lee, Han Bit Lee, Dae Young Kim
  • Patent number: 11396651
    Abstract: Methods and compositions for high-throughput, single cell analyses are provided. The methods and compositions can be used for analysis of genomes and transcriptomes, as well as antibody discovery, HLA typing, haplotyping and drug discovery.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: July 26, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Francois Vigneault
  • Patent number: 11384398
    Abstract: The disclosure is directed to kits and methods for amplifying and detecting human papilloma virus (HPV) of genotype 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and/or 68 in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 12, 2022
    Assignee: ABBOTT MOLECULAR INC.
    Inventors: Wesley Grimm, Joshua Kostera, Robert Hillman, Hong Wang, Ning Tang, Shihai Huang, Klara Abravaya
  • Patent number: 11377688
    Abstract: This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 5, 2022
    Assignee: Gen-Probe Incorporated
    Inventors: Siobhán M. Miick, Paul M. Darby, Jo Ann Jackson, Damon Kittredge Getman
  • Patent number: 11371084
    Abstract: Methods and systems described herein involve using long cell-free DNA fragments to analyze a biological sample from a pregnant subject. The status of methylated CpG sites and single nucleotide polymorphisms (SNPs) is often used to analyze DNA fragments of a biological sample. A CpG site and a SNP are typically separated from the nearest CpG site or SNP by hundreds or thousands of base pairs. Finding two or more consecutive CpG sites or SNPs on most cell-free DNA fragments is improbable or impossible. Cell-free DNA fragments longer than 600 bp may include multiple CpG sites and/or SNPs. The presence of multiple CpG sites and/or SNPs on long cell-free DNA fragments may allow for analysis than with short cell-free DNA fragments alone. The long cell-free DNA fragments can be used to identify a tissue of origin and/or to provide information on a fetus in a pregnant female.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: June 28, 2022
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Kwan Chee Chan, Peiyong Jiang, Suk Hang Cheng, Cheuk Yin Yu, Yee Ting Cheung, Wenlei Peng
  • Patent number: 11359232
    Abstract: The invention relates to the amplification of specific target nucleic acids. The invention provides methods, reagents, and kits for carrying out such amplification via the autoligation chain reaction (ACR).
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: June 14, 2022
    Inventor: Ricardo Mancebo